111 Capital’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$693K Buy
11,113
+5,694
+105% +$360K 0.1% 232
2026
Q2
$312K Buy
+5,419
New +$311K 0.05% 345
2026
Q1
– Sell
-3,820
Closed -$206K – 342
2025
Q4
$206K Sell
3,820
-16,218
-81% -$780K 0.04% 305
2025
Q3
$904K Buy
+20,038
New +$936K 0.17% 127
2025
Q1
– Sell
-17,532
Closed -$992K – 467
2024
Q4
$992K Buy
+17,532
New +$980K 0.21% 100

Other funds holding BMY

111 Capital's BMY Position: Q3 2026 in Review

111 Capital increased its Bristol-Myers Squibb (BMY) stake by 105% in Q3 2026, buying an estimated $360K and bringing the position to 11,113 shares worth $693K. The position accounts for 0.1% of the portfolio, ranked #232.

111 Capital first reported a position in BMY in Q4 2024 and has held it in 5 quarters since. The position peaked at $992K in Q4 2024. 2,549 funds tracked by Wall St. Rank hold BMY as of Q3 2026.

  • 111 Capital held 11,113 shares of Bristol-Myers Squibb worth $693K as of Q3 2026.
  • 111 Capital bought 5,694 Bristol-Myers Squibb shares in Q3 2026, an estimated $360K.
  • Bristol-Myers Squibb made up 0.1% of 111 Capital's portfolio in Q3 2026, its #232 holding.
  • 111 Capital first reported a position in Bristol-Myers Squibb in Q4 2024 and has held it in 5 quarters since.
  • 111 Capital's Bristol-Myers Squibb position peaked at $992K in Q4 2024.
  • 2,549 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2026.

Based on 111 Capital's 13F filing for Q3 2026, filed 3 Nov 2026.